Common questions about Voluven (FAQ)
Q: What do the numbers 130/0.4 mean on the Voluven label?
The numbers on the label describe the main component, Hydroxyethyl Starch (HES), used in the solution. 130 refers to the mean molecular weight (the average size of the molecules), which is 130,000 Daltons. 0.4 refers to the molar substitution ratio, which determines how the molecules are structured, affecting how long the drug stays active in the body.
Q: How quickly does Voluven begin to expand the blood volume?
Official product information describes that the fluid-retaining effect is designed to be rapid. Clinical data indicates that infusing a specific volume over half an hour is described as achieving a volume increase approaching the volume infused. This volume-expanding effect is generally maintained for approximately four to six hours after administration.
Q: What is the difference between Voluven and other HES products, like older starches?
Regulatory documents indicate that Voluven (HES 130/0.4) is chemically modified compared to older Hydroxyethyl Starch products. It is characterized by a lower molecular weight and a lower substitution ratio. These specific physicochemical features are designed to result in faster elimination from the body and a reduced impact on the body's natural blood clotting mechanisms.
Q: What are the signs of fluid overload to watch for after Voluven administration?
Official patient-counseling information identifies signs of fluid overload that may require immediate medical attention. These signs may include feeling shortness of breath or having unusual weakness. Additionally, regulatory documents list swelling of the legs, ankles, feet, face, or hands as symptoms associated with fluid overload.
Q: Why do some patients experience itching (pruritus) after getting Voluven?
Regulatory documentation lists pruritus (itching) as a common documented adverse reaction following administration. However, the official product information does not explicitly detail the exact physiological reason or underlying mechanism for the HES-related itching.
Q: How long can the side effect of skin itching persist after Voluven treatment?
Studies have examined the duration of this common effect, noting that HES-related itching may have a delayed onset, sometimes appearing one to six weeks after receiving the infusion. The product information also describes that the itching can be of protracted persistence, meaning it may last for several weeks or months.
Q: Can Voluven be used in pregnant women?
According to official regulatory documents, there are no adequate and well-controlled studies on the use of Voluven in pregnant women. The medicine’s use during pregnancy is officially restricted to situations where the potential benefit of treatment is judged to outweigh the potential risk to the fetus.
Q: What is known about the use of Voluven during breastfeeding?
Official product labeling states that it is not known whether the components of this medicine are excreted in human milk. Official documents note that caution is advised when the product is administered to a woman who is breastfeeding.
Q: Are there special warnings about using Voluven in patients with cardiac issues?
Official regulatory documents indicate that Voluven is contraindicated (strictly prohibited) in patients who have conditions where hypervolemia (fluid overload) is a major concern. This restriction specifically includes patients with congestive heart failure and those with existing pulmonary edema (fluid in the lungs).
Q: What are the concerns about using Voluven in patients undergoing open heart surgery?
Official regulatory warnings state that for patients receiving HES products during procedures involving cardiopulmonary bypass (such as open heart surgery), regulatory documents indicate that the coagulation status is subject to close monitoring. This caution is in place due to the HES product's known potential to affect blood clotting mechanisms.
Q: Why must Voluven be used with caution alongside drugs that affect coagulation?
Caution is necessary because Voluven is documented to transiently alter the coagulation mechanism of the blood. Official documents note that it can cause a dose-dependent decrease in coagulation factors. This effect may increase the risk of bleeding, especially when the product is used with other medicines that already affect blood clotting.
Q: Is Voluven a substitute for blood in cases of severe blood loss?
Voluven is classified as a plasma volume substitute used for circulatory support and fluid restoration. Official regulatory labeling clarifies that it is not a substitute for red blood cells or the essential coagulation factors found in whole blood or plasma.
Q: Does Voluven accumulate in the body tissues over time?
Regulatory documents describe that the Hydroxyethyl Starch (HES) molecules are primarily broken down and eliminated by the kidneys. While the product information focuses on excretion, studies have noted that HES is either excreted or taken up in tissues. The extent of this tissue storage is linked to the physicochemical properties of the HES molecule.
Q: Why did the European Medicines Agency (EMA) place restrictions on the use of HES products?
European regulatory bodies placed restrictions on the use of HES products following clinical studies that identified an increased risk of mortality and severe renal injury (which may require renal replacement therapy). This increased risk was specifically documented in certain critically ill adult populations, including patients with sepsis.
Q: Did Voluven trials show any difference in mortality compared to saline in the general ICU population?
Official safety reviews, which included analyses of trials in acutely ill patients, reported that Voluven was associated with an increased risk of needing renal replacement therapy. While these results led to strict contraindications primarily for critically ill patients (like those with sepsis), the regulatory decisions reflect the findings from these comparative studies.
Q: Can Voluven cause changes in heart rate, such as it beating too fast or too slow?
Official adverse reaction documents report that rare reactions may include changes in heart rate. These have been reported as both tachycardia (abnormally fast heart rate) and bradycardia (abnormally slow heart rate), often observed as part of a severe, though rare, allergic (anaphylactoid) reaction.
Q: Is Voluven still actively sold and used in the United States and Europe?
According to the FDA and European regulatory bodies, Voluven holds an active marketing authorization. However, its clinical use is subject to the severe restrictions and contraindications that were imposed following safety reviews concerning its use in critically ill patient groups.
Q: What are the guidelines for monitoring blood coagulation factors during Voluven treatment?
Official regulatory guidelines indicate that periodic laboratory determinations of coagulation parameters are a necessary component of treatment. This monitoring is mandated because administration of the product can cause dose-dependent effects on blood clotting.
Q: What is the recommended approach if too much Voluven is administered?
Official product information on overdosage indicates that receiving too much Voluven can lead to overloading of the circulatory system (hypervolemia). If this occurs, regulatory documents state the infusion is typically discontinued immediately, and the use of a diuretic medicine may be required to help eliminate excess fluid.
Q: What are 'flu-like symptoms' associated with Voluven, and are they serious?
Rare but serious allergic (anaphylactoid) reactions have been reported with HES solutions. Official documents note that these reactions may begin with mild influenza-like symptoms such as chills, headache, or muscle aches (myalgia), which can sometimes accompany more severe symptoms like breathing difficulty.
Q: Is the low molecular weight of Voluven an advantage over older starches?
Official information describes the product's physicochemical properties, noting that the lower molecular weight and molar substitution ratio of Voluven contribute to its faster elimination via the kidneys. This design feature supports its faster elimination and reduced tissue retention compared to older HES formulations.
Q: What is the significance of the 6S Trial or the CHEST Trial in relation to Voluven?
Official regulatory decisions reference major clinical studies, such as the CHEST trial, as sources of information leading to the current restrictions on Voluven. These trials were key in identifying an increased risk of patients requiring renal replacement therapy (RRT) in critically ill populations, prompting the current contraindications.
Q: What is the difference between HES 130/0.4 (Voluven) and HES 200/0.5?
Official pharmacological documents distinguish HES solutions by their properties, with Voluven being HES 130/0.4. Older starches, such as HES 200/0.5, have a higher molecular weight and a higher molar substitution ratio. These differences are linked to variations in how long the products remain active in the blood and their overall safety profiles.
